Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://murrayq864kll3.blogdosaga.com/profile